Research programme: exosome therapeutics - Capricor Therapeutics

Drug Profile

Research programme: exosome therapeutics - Capricor Therapeutics

Alternative Names: CAP 2003

Latest Information Update: 27 Sep 2016

Price : $50

At a glance

  • Originator Capricor Therapeutics
  • Developer Capricor Therapeutics; Cedars-Sinai Health System
  • Class Gene therapies; MicroRNAs; Proteins
  • Mechanism of Action Protein replacements; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cardiovascular disorders; Graft-versus-host disease

Most Recent Events

  • 15 May 2017 Capricor Therapeutics announces intention to file an IND application for CAP 2003 in 2018
  • 27 Sep 2016 Capricor Therapeutics announces intention to submit IND to US FDA in in the first half of 2017
  • 15 Aug 2016 Preclinical trials in Graft-versus-host disease in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top